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Abstract It is estimated that bone loss occurs in 70 % of all
patients dying from cancer, causing a significant disease bur-
den in cancer patients. Bone loss is caused by cancer itself and
its metastases, but also by cancer therapies. Of the cancer
therapy-induced bone loss, hormone therapies are best known
for their bone damaging abilities. However, chemo- and ra-
diotherapy may result in bone loss too. In this review, direct
and indirect effects of various chemotherapies (such as meth-
otrexate, imatinib, and taxanes) that cause bone loss are
discussed. Furthermore, we discuss bone loss caused by ra-
diotherapy and radionuclides, of which the latter may be re-
duced with the introduction of the alpha-emitter Radi-
um-223. Finally, agents preventing chemotherapy- or
radiotherapy-induced bone loss, in particular denosumab
and bisphosphonates, are being reviewed for their effi-
cacy in preventing chemotherapy- and irradiation-
induced bone loss in cancer patients.
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Introduction
Cancer is one of the most prevalent and deadliest diseases in
the world, with an estimated 1.7 million new cases and 586,
000 deaths in the USA in 2014 [1]. In cancer patients, bone
loss occurs frequently: it is estimated that bones are affected of
over 70 % of all patients dying from cancer, often resulting in
significant morbidity and mortality [2]. Bone disease primar-
ily occurs due to bone metastases: lung carcinomas, causing
most cancer deaths in both men and women [1], as well as
prostate and breast cancer, the most prevalent cancers in men
and women, respectively [3], frequently metastasize to the
bones; other solid tumors metastasize to bones as well [2].
Furthermore, bone may be damaged in cancer patients
by other causes, such as cancer therapy. For example, in
a case–control study, breast cancer patients without bone
metastases had a significant increase in vertebral frac-
tures (odds ratio (OR) of 4.7) as compared to controls
from a general population [4].
It is well known that hormonal suppression by hormone
ablation therapy, frequently used in patients with among
others prostate and breast cancer, results in osteoporosis and
bone fractures due to a decrease in bonemineral density [5]. In
prostate cancer patients who received long-term androgen-
deprivation therapy, osteoporosis rates increased from
35.4% in hormone-naive patients to 80.6% of patients treated
with androgen-deprivation therapy for ten or more years [6].
In a study with 50,613 prostate cancer patients who did and
did not receive androgen-deprivation therapy, androgen-
deprivation therapy increased the risk of fractures from 12.6
to 19.4 % [7]. Similarly, hormonal therapy in breast cancer
patients, particularly treatment with aromatase inhibitors such
as letrozole and exemestane, has been found to increase the
risk for osteoporosis and (pathological) fractures [8, 9]. Con-
sidering the role of hormones in bone physiology, aforemen-
tioned increased occurrences of bone loss and skeletal-related
events after hormonal-ablation therapy is not surprising.
Treatment of cancer patients with other therapies, such as
radio- and chemotherapy, may result in significant bone loss
as well. These therapies may directly target the bones or may
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provoke bone loss by indirect systemic effects. Furthermore,
agents currently administered to cancer patients aiming to re-
ducing bone-related adverse events may actually result in
osteonecrosis. In this review, the prevalence and (potential)
mechanisms of bone loss after administration of chemothera-
py and irradiation will be discussed. Furthermore, novel mo-
dalities that may reduce chemotherapy- or irradiation-induced
bone loss will be reviewed.
Chemotherapy and Bone Loss
Chemotherapy may lead to bone damage via indirect systemic
effects, of which the most studied effect is the loss of ovarian
function in women. In one study, adjuvant chemotherapy with
cyclophosphamide, methotrexate, and fluorouracil in premen-
opausal women with breast cancer resulted in chemotherapy-
induced amenorrhea in 68 % (95 % CI 66–70 %) of these
patients [10]. This ovarian failure resulted in rapid bone loss:
within 2 years, this combination of chemotherapy resulted in
bone loss of 9.5 % in the lumbar spine and 4.6 % in the
femoral neck [11]. Other combinations of adjuvant chemo-
therapy induce amenorrhea in premenopausal breast cancer
patients as well [12, 13•].
However, chemotherapy may also have a direct impact on
bone (re)modeling. As summarized by Hadji et al., studies
evaluating adjuvant chemotherapy in premenopausal breast
cancer patients consistently reported a decrease in bone min-
eral density during the first year after initiation of therapy
[13•]. For example, one study with premenopausal breast can-
cer patients reported that bonemineral density in the spine and
hips of women during 6 months’ adjuvant systemic chemo-
therapy was decreased by 1.01–1.05 g/m2, independently of
changes to ovarian function or amenorrhea [14].
Imatinib, used for the treatment of gastrointestinal stromal
tumors and leukemia, directly targets various receptors that
play a role in the bone microenvironment, such as the
platelet-derived growth factor (PDGF) receptor and the mac-
rophage colony stimulating factor (c-Fms) receptor [15, 16].
In manipulating these receptors, bone formation was found to
be increased by increasing osteoblast activity at metaphyseal
osteochondral junctions and by eliminating osteoclasts from
these junctions, leading to decreased bone resorption at the
growth plate [17]. On the other hand, imatinib increased oste-
oclast activity at distal trabecular bone, resulting in increased
bone resorption [17].
Many chemotherap ies such as taxanes cause
myelosuppression [18, 19]. Recently, Quach et al. reported
that myelosuppression resulted in bone loss in mice by in-
creased bone resorption, which was associated with increased
expression of monocyte chemoattractant protein 1 (MCP1)
and other inflammatory cytokines [20•]. MCP1 was also
found to be increasingly expressed in cancer patients who
had recently received chemotherapy and had bone loss. Inhi-
bition of osteoclast activity by zoledronic acid prevented this
MCP1-associated bone loss [20•].
Methotrexate, used for the treatment of, among others,
breast cancer, lung cancer, head and neck cancer, choriocarci-
noma, and osteosarcoma, directly targets bone tissue too. In an
in vivo experiment, the anti-metabolite increased apoptosis of
osteocytes by a 4.3-fold, while increasing the number of oste-
oclasts by a 1.8-fold, associated with increased expression of
the inflammatory cytokines IL-6 and IL-11 [21]. These chang-
es resulted in a 35 % loss of trabecular bone. In a different
study, it was found that methotrexate-induced changes to bone
(re)modeling may occur due to decreased activation of the
Wnt/β-catenin signaling pathway [22].
Finally, corticosteroids such as prednisone play an impor-
tant role in the treatment of patients with, among others, pros-
tate cancer and multiple myeloma. Although the antitumor
activity of this glucocorticoid as a single agent is being debat-
ed in most tumors, it is regularly administered concomitantly
with other antitumor agents, such as taxanes and abiraterone.
In multiple myeloma, the antitumor efficacy of corticosteroids
by themselves is evident due to its ability to inhibit IL-6 pro-
duction and to induce apoptosis in plasma cells [23]. Howev-
er, prednisone directly affects bone tissue: osteoblast activity
is reduced by decreased osteoblast cell replication and differ-
entiation, while apoptosis is increased; osteoclastogenesis is
increased by increased expression of RANK-ligand and de-
creased expression of osteoprotegerin, a decoy receptor of
RANK-ligand [24]. Furthermore, urinary excretion of calcium
is increased, while intestinal absorption of calcium is
inhibited, resulting in further bone damage [23].
Radiotherapy and Bone Loss
On the contrary to chemotherapy, which causes bone loss both
by direct and indirect effects, radiation primarily causes direct
damage to bone tissue. In pediatrics, most damage from ra-
diotherapy occurs to the growth plate, causing growth distur-
bances, while in adults, osteopenia and incomplete healing of
bone damage results in skeletal-related events such as insuffi-
ciency fractures [25]. The exact pathogenesis of radiotherapy-
induced bone loss has not been unraveled completely yet.
Consensus exists that radiation decreases the number of active
osteoblasts by arresting these in the cell cycle, altering their
ability to differentiate, and sensitizing the cells to apoptosis
[26, 27, 28•]. As summarized by Chandra et al., the role of
radiation therapy in the activation of osteoclasts is still being
debated, with some studies reporting a decrease in osteoclast
activity while others report an increase in number and activity
of osteoclasts [28•]. Nevertheless, the hypothesis that radio-
therapy may induce osteoclast activity is strengthened by a
clinical study that found that the addition of antiresorptive
Curr Osteoporos Rep (2015) 13:140–145 141
agents such as zoledronic acid prevented or delayed skeletal-
related events in patients with bone metastases, and by in vivo
studies that indicated a decrease in radiotherapy-induced bone
loss when mice were treated with bisphosphonates [29–31]. A
recently published study suggests that PTH1-34 may prevent
radiotherapy-induced bone loss by preventing apoptosis
of osteoblasts and osteocytes [28•].
Radionuclides and Bone Loss
Radionuclides, such as Rhenium-186, Strontium-89, and
Samarium-153, localize to areas with increased bone turn-
over, thereby selectively targeting osteoblastic bone metas-
tases [32, 33]. For this reason, radionuclides have been
used to treat bone metastases in a variety of cancers, such
as prostate and breast cancer. However, most radionuclides
are beta-emitters and/or even gamma-emitters, which are
moderately to highly penetrating, thereby damaging sur-
rounding tissue as well. Indeed, it has been shown that
these radionuclides result in damage of healthy bone mar-
row, as noted by the increase in thrombocytopenia and
leucopenia [33]. Therefore, radionuclides most likely dam-
age healthy bone tissue as well, although this has not been
proven. Such damage could be reduced by making use of
alpha-emitting particles, which are highly energetic but do
not have a high penetrative capacity. Radium-223 chloride
is such a particle. It has received approval by the United
States Food and Drug Administration (US FDA) for the
systemic treatment of patients with castrate-resistant pros-
tate cancer with bone metastases in 2013. As described
previously, Radium-223 emits four alpha-particles and
two beta-particles during its decay, until it stabilizes as
Lead-207, thereby selectively targeting cells in its direct
surroundings [34•]. Radium-223 increased overall survival
in mCRPC patients while bone marrow toxicity was rela-
tively low as compared to other radionuclides [35]. Nev-
ertheless, these results need to be confirmed in studies
assessing long-term efficacy and toxicity of radium-223
treatment. Currently, clinical trials are being performed to
study the antitumor efficacy in patients with cancers me-
tastasized to bones other than prostate cancer, and in pa-
tients with primary bone cancer.
Agents Used for the Prevention of Bone Loss
It is generally thought that the key to cancer-induced bone loss
is an increase in osteoclast activity, resulting in decreased bone
mass. Over the past two decades, bisphosphonates and the
RANK ligand inhibitor denosumab have become available
to prevent both cancer-induced bone loss and cancer
therapy-induced bone loss. Bisphosphonates reduce osteoclast
activity, thereby increasing bone mass, resulting in increased
strength of the bone and a reduction in pathological fractures
[36, 37]. Various bisphosphonates have been approved for
bone-related diseases, including ibradronic acid, pamidronic
acid, risedronate, and zoledronic acid for the reduction of
skeletal-related events in cancer patients and for patients with
multiple myeloma. Of these, zoledronic acid is most common-
ly used, as various studies in patients with cancer-related bone
disease indicated superiority of zoledronic acid over other
bisphosphonates [38–40]. Treatment with bisphosphonates
decreases pain secondary to bone metastases, pathological
fractures, and other skeletal-related events, thereby improving
quality of life [41–43].
Denosumab is a subcutaneously administered, monoclonal
antibody approved by the US FDA for the treatment of
unresectable giant cell tumor of bone in adults and skeletally
mature adolescents, for cancer patients at high risk for fracture
for example due to androgen-deprivation therapy or adjuvant
aromatase inhibitor therapy, and for the prevention of skeletal-
related events in patients with bone metastases from solid
tumors [44]. In various phase III studies with patients with
bone metastases from solid tumors, denosumab was more ef-
fective in delaying or preventing skeletal-related events and
pain progression than bisphosphonates [45–49]. In prostate
cancer patients, denosumab also reduced the risk of symptom-
atic skeletal events, a biomarker considered more accurate for
assessing clinical benefit in patients [50•]. Furthermore, in
patients with metastatic lung cancer, overall survival was im-
proved when patients were treated with denosumab as com-
pared to zoledronic acid [51]. However, due to its higher cost,
the cost-effectiveness of denosumab as compared to
bisphosphonates remains unclear, and many physicians con-
tinue to treat cancer patients with bone disease with
bisphosphonates [52].
Although bisphosphonates and denosumab aim to reduce
bone disease, these agents may also cause bone damage, in-
cluding hypocalcaemia, atypical femur fractures, and
osteonecrosis of the jaw [37, 53]. Osteonecrosis of the jaw
occurs in an estimated 7 % (range 0–27.5 %) of all patients
treated with bisphosphonates; its mean incidence was 1.7 % in
recent studies in which patients were treated with denosumab
but did not differ significantly from the incidence of
osteonecrosis of the jaw after treatment with bisphosphonates.
Although this painful and potentially debilitating adverse
event may initially be treated with antibiotics, the damage is
often irreversible for which surgical management is needed. It
is hypothesized that osteonecrosis of the jaw after therapy with
antiresorptive agents is caused by oversuppression of osteo-
clast activity and/or by compromising of angiogenesis, there-
by resulting in bone ischemia and sclerosis [54]. Other factors
may contribute to osteonecrosis of the jaw, such as infections,
poor oral hygiene, surgery to the jaw bones, diabetes mellitus,
smoking, dental extraction, and concurrent medications like
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glucocorticoids or antiangiogenic medication (among others
bevacizumab, sunitinib, sorafenib, mTOR inhibitors) [54,
55••]. Indeed, recent studies have indicated that the incidence
of osteonecrosis of the jaw during therapy with
bisphosphonates or denosumab can be decreased by improv-
ing oral hygiene, by eliminating or stabilizing oral disease
before initiating treatment, and by temporarily discontinuing
treatment after extensive oral surgery [53, 55••].
Other agents have been or are currently being investigated
for their use in the prevention of bone loss, with limited suc-
cess. For example, studies are ongoing to investigate the use
of gonadotropin-releasing hormone agonists such as
triptorelin for the prevention of chemotherapy-induced ovari-
an failure. However, a prospective randomized clinical trial in
patients with lymphoma did not find a statistically decreased
risk of ovarian failure [56]. A meta-analysis of studies per-
formed in breast cancer patients reported a significant de-
crease in premature ovarian failure after treatment with a
gonadotropin-releasing hormone agonist (RR 0.40, 95 % CI
0.21–0.75), but no effect on resumed menses [57]. A recent
study confirms this decrease in premature ovarian failure in
breast cancer patients treated with adjuvant chemotherapy
[58]. However, long-term studies need to be performed to
assess whether such therapy results in a decrease in
chemotherapy-induced bone disease.
Conclusions
Bone disease causes high rates of morbidity and mortality in
cancer patients. It can be caused both by the tumor itself and
by cancer therapy. Both hormonal therapy, chemotherapy, and
radiotherapy may induce bone loss. While radiotherapy-
induced bone loss is primarily caused by direct bone damage,
chemotherapy-induced bone damage may be the result of di-
rect bone targeting or by indirect systemic effects, such as
decreased ovarian function. Multiple agents, such as
bisphosphonates and denosumab, have become available to
reduce bone damage after antitumor therapy. However, these
agents may induce severe bone damage too, particularly
osteonecrosis of the jaw. Further research is needed to de-
crease the disease burden from therapy-induced bone loss in
cancer patients.
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